Announcements Trials

Browse Landscape

Phase

Phase 1 4 Phase 2 3 Phase 1/2 3 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 168 Precursor Cell Lymphoblastic Leukemia-Lymphoma 33 Recurrence 28 Leukemia 24 Vomiting 23 Neoplasms, Plasma Cell 20 Lymphoma 18 Neoplasms 16 Nausea 13 Burkitt Lymphoma 11 Prostatic Neoplasms 8 Immunoglobulin Light-chain Amyloidosis 7 Carcinoma, Non-Small-Cell Lung 6 Lymphoma, Follicular 5 Lung Neoplasms 5 Hodgkin Disease 5 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Lymphoma, Non-Hodgkin 4 Leukemia, Biphenotypic, Acute 4 Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Small Cell Lung Carcinoma 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Paraproteinemias 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large B-Cell, Diffuse 3 Fallopian Tube Neoplasms 3

Interventions

Rituximab 14 pirtobrutinib 6 ibrutinib 4 Vincristine 4 Doxorubicin 4 Prednisone 3 Cytarabine 3 Cyclophosphamide 3 zanubrutinib 2 acalabrutinib 2 Methotrexate 2 Etoposide 2 Bendamustine Hydrochloride 2 venetoclax 1 tositumomab I-131 1 idelalisib 1 ibritumomab tiuxetan 1 etoposide phosphate 1 entecavir 1 cirmtuzumab 1 axicabtagene ciloleucel 1 VAP-cyclo protocol 1 Tenofovir 1 Radiotherapy 1 Melphalan 1 Ifosfamide 1 Gemcitabine 1 Everolimus 1 Drug Therapy 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, B-Cell × Dexamethasone × Clear all

NCT06230224 2026-05-11

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡